Who owns Eagle Pharmaceuticals?
- Ticker: EGRX
- CUSIP Number: 269796108
Tip: Access positions for across all investors
Analyze quarterly positions in Eagle Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Eagle Pharmaceuticals stock
Who bought or sold Eagle Pharmaceuticals this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Nantahala Capital Management | 3.4M | $13M | 13% | Sep 2024 |
|
AIGH Capital Management | 1.2M | $4.5M | 0% | Sep 2024 |
|
Citigroup | 1.0M | $3.7M | 0% | Sep 2024 |
|
Vanguard Group | 564k | $3.2M | -12% | Jun 2024 |
|
AQR Capital Management | 375k | $1.4M | -46% | Sep 2024 |
|
BlackRock | 353k | $2.0M | -61% | Jun 2024 |
|
Morgan Stanley | 300k | $1.7M | -20% | Jun 2024 |
|
BlackRock | 268k | $1.0M | 100% | Sep 2024 |
|
Renaissance Technologies | 256k | $956k | 5% | Sep 2024 |
|
Two Sigma Advisers | 225k | $1.3M | -5% | Jun 2024 |
|
Marshall Wace | 223k | $833k | 14% | Sep 2024 |
|
J. Goldman & Co | 191k | $1.1M | -26% | Jun 2024 |
|
Assenagon Asset Management | 184k | $685k | -1% | Sep 2024 |
|
Two Sigma Investments | 134k | $750k | -18% | Jun 2024 |
|
Jacobs Levy Equity Management | 122k | $453k | 100% | Sep 2024 |
|
Tang Capital Management | 119k | $443k | 0% | Sep 2024 |
|
Geode Capital Management | 106k | $395k | -2% | Sep 2024 |
|
Invesco | 83k | $309k | 0% | Sep 2024 |
|
Goldman Sachs Group | 79k | $443k | -56% | Jun 2024 |
|
DGS Capital Management | 72k | $268k | 45% | Sep 2024 |
|
AJOVista | 56k | $211k | 402% | Sep 2024 |
|
D. E. Shaw & Co | 55k | $204k | -68% | Sep 2024 |
|
Bank of America Corporation | 51k | $190k | -84% | Sep 2024 |
|
Deutsche Bank Aktiengesellschaft | 49k | $182k | 0% | Sep 2024 |
|
Trexquant Investment | 44k | $163k | -17% | Sep 2024 |
|
Royal Bank of Canada | 37k | $138k | -2% | Sep 2024 |
|
State Street Corporation | 36k | $201k | -83% | Jun 2024 |
|
Northern Trust | 32k | $119k | -68% | Sep 2024 |
|
Bridgeway Capital Management | 32k | $179k | 0% | Jun 2024 |
|
PDT Partners | 30k | $112k | 0% | Sep 2024 |
|
Citadel Advisors | 27k | $101k | 100% | Sep 2024 |
|
Jane Street | 26k | $96k | 100% | Sep 2024 |
|
Bnp Paribas Arbitrage, Snc | 18k | $67k | -26% | Sep 2024 |
|
Squarepoint Ops | 18k | $100k | 100% | Jun 2024 |
|
Qube Research & Technologies | 17k | $94k | 372% | Jun 2024 |
|
Creative Planning | 16k | $59k | 100% | Sep 2024 |
|
JustInvest | 16k | $58k | 14% | Sep 2024 |
|
Barclays | 15k | $56k | -21% | Sep 2024 |
|
Royce & Associates | 14k | $52k | 0% | Sep 2024 |
|
T. Rowe Price Associates | 13k | $50k | 0% | Sep 2024 |
|
Hsbc Holdings | 13k | $66k | 0% | Jun 2024 |
|
William Blair $ Company | 13k | $48k | -1% | Sep 2024 |
|
Virtu Financial | 13k | $48k | 100% | Sep 2024 |
|
Stanley-Laman | 12k | $45k | 0% | Sep 2024 |
|
Jump Financial | 11k | $40k | -12% | Sep 2024 |
|
Russell Investments | 9.8k | $55k | 324% | Jun 2024 |
|
Simplex Trading | 8.4k | $31k | 100% | Sep 2024 |
|
State of Wyoming | 8.1k | $46k | -63% | Jun 2024 |
|
Point72 Asia | 7.8k | $29k | -33% | Sep 2024 |
|
Acadian Asset Management | 7.2k | $26k | -73% | Sep 2024 |
|
Cubist Systematic Strategies | 6.2k | $23k | -76% | Sep 2024 |
|
WealthCollab | 5.6k | $21k | 6% | Sep 2024 |
|
Tower Research Capital | 3.2k | $18k | -10% | Jun 2024 |
|
HighMark Wealth Management | 2.2k | $8.2k | 100% | Sep 2024 |
|
Headlands Technologies | 1.7k | $6.2k | 100% | Sep 2024 |
|
Group One Trading | 785.00 | $2.9k | 100% | Sep 2024 |
|
Macquarie Group | 518.00 | $2.9k | 100% | Jun 2024 |
|
Archer Investment Corp | 350.00 | $1.3k | 0% | Sep 2024 |
|
Capital Advisors | 149.00 | $999.998600 | 0% | Sep 2024 |
|
Advisor Group Holdings | 105.00 | $390.999000 | -37% | Sep 2024 |
|
Farther Finance Advisors | 64.00 | $239.001600 | 0% | Sep 2024 |
|
Global Retirement Partners | 49.00 | $183.000300 | 0% | Sep 2024 |
|
Front Row Advisors | 40.00 | $149.000000 | 0% | Sep 2024 |
|
Credit Agricole | 36.00 | $133.999200 | 100% | Sep 2024 |
|
Pnc Financial Services | 28.00 | $104.000400 | 0% | Sep 2024 |
|
Who sold out of Eagle Pharmaceuticals?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
LSV Asset Management | Jun 2024 | 295k | $1.7M |
Perceptive Advisors | Jun 2024 | 173k | $971k |
Millennium Management | Jun 2024 | 168k | $940k |
Thomas Stevens, CFA" | Jun 2024 | 133k | $743k |
Kennedy Capital Management | Mar 2024 | 56k | $292k |
Charles Schwab Investment Management | Jun 2024 | 51k | $283k |
Nuveen Asset Management | Mar 2024 | 42k | $221k |
Wintrust Financial Corporation | Jun 2024 | 24k | $132k |
Alliancebernstein | Mar 2024 | 21k | $112k |
XTX Topco | Jun 2024 | 20k | $113k |
Fidelis Capital Partners | Jun 2024 | 13k | $54k |
Mackenzie Financial | Jun 2024 | 11k | $60k |
Susquehanna International | Jun 2024 | 10k | $58k |
Sei Investments | Mar 2024 | 10k | $54k |
Rhumbline Advisers | Jun 2024 | 7.2k | $41k |
Mirae Asset Global Etfs Holdings | Jun 2024 | 4.9k | $27k |
Jpmorgan Chase & Co | Jun 2024 | 2.3k | $13k |
CWM | Jun 2024 | 1.7k | $9.0k |
Quantbot Technologies | Mar 2024 | 1.2k | $6.3k |
Wells Fargo & Company | Jun 2024 | 351.00 | $2.0k |
New York State Common Retirement Fund | Jun 2024 | 90.00 | $999.999000 |